Prediction of everolimus-induced interstitial lung disease in breast cancer patients

Phase 4, open-label, single-arm trial of everolimus and exemestane in breast cancer, sponsored by Radboud University Medical Center. Primary endpoint: Correlation of clinical, biomarker, PK, pulmonary function, imaging, and toxicity variables with everolimus-induced ILD. Started Apr 2014; status: active, not recruiting.